688062.SH
Mabwell (Shanghai) Bioscience Co., Ltd.
SSE · Healthcare · Biotechnology · CN
CNY 21.80
+1.68%Oct 28, 2026, 09:10 UTC
Maiwei Biologics approved extending the planned completion of its Phase 1 antibody drug pilot-scale industrialization project from December 2026 to December 2027.
Source:Oct 28, 2026, 09:10 UTC
Maiwei Biologics reported third-quarter 2026 revenue of RMB 308 million, down 33.61% year over year, and a net loss attributable to shareholders of RMB 157 million; revenue for the first nine months was RMB 621 million, up 9.77%, with a net loss of RMB 678 million and R&D spending of RMB 688 million.
Source:Sep 28, 2026, 10:57 UTC
Mabwell Bioscience plans to inject capital into its wholly owned subsidiary Lianwei Chuangyuan and transfer TCE project assets to it.
Source:Aug 30, 2026, 07:55 UTC
Mabwell Bioscience reported its H1 2026 semi-annual results on August 30, with revenue of 313 million yuan (up 209.04% year-on-year) and a net loss attributable to shareholders of 522 million yuan, narrowing from a loss of 551 million yuan in the same period last year.
Jul 16, 2026, 02:21 UTC
Mabwell (Shanghai) Bioscience Co., Ltd. received approval from the National Medical Products Administration for a clinical trial application of its 9MW5211 injection for vitiligo.
Source: